749 related articles for article (PubMed ID: 22343605)
21. [The unreasonableness of prostate-cancer screening and the ethical problems pertaining to its investigation].
Bonneux L
Ned Tijdschr Geneeskd; 2005 Apr; 149(18):966-71. PubMed ID: 15903036
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
23. Screening for prostate cancer: an updated review.
Marta GN; Hanna SA; Fernandes da Silva JL; Carvalho Hde A
Expert Rev Anticancer Ther; 2013 Jan; 13(1):101-8. PubMed ID: 23259431
[TBL] [Abstract][Full Text] [Related]
24. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
Colli JL; Amling CL
Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
[TBL] [Abstract][Full Text] [Related]
26. [Focus on the screening for prostate cancer by PSA].
Roumeguère T; Van Velthoven R
Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system.
Scosyrev E; Wu G; Golijanin D; Messing E
BJU Int; 2012 Nov; 110(10):1485-90. PubMed ID: 22448649
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
29. Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages.
Ross KS; Guess HA; Carter HB
Urology; 2005 Nov; 66(5):1038-42. PubMed ID: 16286120
[TBL] [Abstract][Full Text] [Related]
30. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
Hegarty JM; Wallace M; Comber H
Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
[TBL] [Abstract][Full Text] [Related]
31. [CONs].
Sobue T
Gan To Kagaku Ryoho; 2014 May; 41(5):553-7. PubMed ID: 24917002
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen in clinical practice.
Loeb S; Catalona WJ
Cancer Lett; 2007 Apr; 249(1):30-9. PubMed ID: 17258389
[TBL] [Abstract][Full Text] [Related]
33. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
34. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.
Caire AA; Sun L; Robertson CN; Polascik TJ; Maloney KE; George DJ; Price MM; Stackhouse DA; Lack BD; Albala DM; Moul JW
Urology; 2010 May; 75(5):1122-7. PubMed ID: 19815259
[TBL] [Abstract][Full Text] [Related]
35. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
;
Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
[TBL] [Abstract][Full Text] [Related]
36. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
[TBL] [Abstract][Full Text] [Related]
37. Elderly and prostate cancer screening.
Stamatiou KN
Urol J; 2011; 8(2):83-7. PubMed ID: 21656465
[TBL] [Abstract][Full Text] [Related]
38. Risks of PSA screening now better understood.
Peres J
J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
[No Abstract] [Full Text] [Related]
39. Prostate-specific antigen testing and prostate cancer screening.
Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
[TBL] [Abstract][Full Text] [Related]
40. Early detection, PSA screening, and management of overdiagnosis.
Borza T; Konijeti R; Kibel AS
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
